When EGFR meets MET: Dual blockade as the next post-TKI standard? - PubMed
5 hours ago
- #EGFR
- #MET
- #NSCLC
- The SACHI trial showed that savolitinib plus osimertinib nearly doubled progression-free survival (PFS) compared to chemotherapy (9.8 vs. 5.4 months) in EGFR-mutated, MET-amplified NSCLC patients after EGFR TKI failure.
- This trial provides the first phase 3 evidence supporting dual EGFR/MET inhibition in this patient group.
- Conflict of interest disclosures include advisory roles and research grants from multiple pharmaceutical companies for the authors.